The scientific value of premature infant biospecimens collection

Ended Project Grant Awarded Last action

Award ID
R21GM150136
Recipient
Awarding agency
Obligated
$1,228,347

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
Virginia, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The complexities of heterogeneity, stratification, and staging of sepsis have contributed to the poor translatability of current molecular models for diagnosis and treatment of human sepsis. The national advisory general medical sciences council advised using discovery approaches to characterize sepsis using human biospecimens. Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to a bacterial, viral, or fungal infection, is a major cause of death in premature (=32 weeks) and low birth weight (= 1500G) infants and occurs in up to 25% of such infants.1-3 the ability to collect microbiome and tissue biospecimens longitudinally from multiple body sites under extremely controlled circumstances prior to, during, and throughout sepsis (culture proven), sepsis-like (culture negative critical illness), and "normal" growing premature infant conditions will allow our team to determine optimal sample collection, storage, and processing protocols using small volume samples to enhance sepsis research rigor, and to develop new strategies for sepsis detection by discerning pathways that contribute to the pathophysiology of sepsis in the premature neonatal population. In the R21 phase we will collect clinical information and stool, blood, and saliva specimens longitudinally from preterm infants (=32 weeks and =1500G) on days 1, 3, 7, 14, 21, 28, 35, 42, and 49 of life, and additionally during suspected sepsis events. Standardization and documentation of sample collection, storage, and processing and sample validation studies will ensure rigor and reproducibility and inform the field. In the R33 phase we will collect samples from 2 clinical sites providing a test set for machine learning methods. Utility of the newly collected biospecimens and associated clinical data will be demonstrated by constructing a multi-omic network for predicting causal mechanisms from genes/metabolites/clinical parameters differentially expressed between clinically well neonates and those with culture proven sepsis and culture negative systemic inflammatory illness. We will make establish testable causal inferences and predictive models of microbial/host gene interactions and biologic mechanisms leading to sepsis that could form the foundation for future mechanistic studies. Our team of neonatal providers, immunologists, systems biologists, microbiome specialists, and bioinformaticians supported by two large level IV nicus are uniquely positioned to collect and analyze biospecimens and clinical data before, during, and after critical illness in patients with extreme prematurity.

Transactions

Action Obligated Date
Amendment $0
Amendment -$3,491
Amendment $11,454
Amendment -$7,963
Amendment $0
Amendment $206,897
Amendment $206,897
Amendment $206,897
Amendment -$210,952
Amendment -$210,952
Amendment -$210,952
Amendment $218,915
Amendment $218,915
Amendment $218,915
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $194,589
Amendment $194,589
Original award $194,589
Show all 21

Subawards

Subrecipient Amount Awarded
Oregon State University The scientific value of premature infant biospecimens collection. $8,090

Quick answers

Who received award R21GM150136?

R21GM150136 was awarded to Inova Health Care Services by National Institute of General Medical Sciences (National Institutes of Health) on July 3, 2023.

How much is award R21GM150136 worth?

$1,228,347 has been obligated on R21GM150136.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login